Affiliation:
1. Department of Pathology, University of Iowa College of Medicine, Iowa City,1 and
2. The Jones Group/JMI Laboratories, North Liberty,2 Iowa
Abstract
ABSTRACT
Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of
Candida
spp. (3,312 isolates) and
C. neoformans
(373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all
Candida
spp. (MIC at which 90% of the isolates were inhibited [MIC
90
], 0.5 μg/ml; 97% of MICs were ≤1 μg/ml) and
C. neoformans
(MIC
90
, 0.5 μg/ml; 100% of MICs were ≤1 μg/ml).
Candida albicans
was the most susceptible species of
Candida
(MIC
90
, 0.06 μg/ml), and
Candida glabrata
was the least susceptible (MIC
90
, 4 μg/ml). Posaconazole was more active than itraconazole and fluconazole against all
Candida
spp. and
C. neoformans
. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
130 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献